ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 4ο | Página 67

ΙSSN: 2623- 3673
Φεβρουάριος, 2019
Ψυχολογία :έρευνα & εφαρμογές
26. Pourmand A, Mazer-Amirshahi M, Chistov S, Sabha Y, Vukomanovic D,
Almulhim M. Am J Emerg Med. 2017 Dec;35(12):1928-1933. Emergency
department approach to QTc prolongation.
27. Agahi M, Akasheh N, Ahmadvand A, Akbari H, Izadpanah F. Diabetes
Metab Syndr. 2018 Jan - Mar;12(1):9-15. Effect of melatonin in reducing
second-generation antipsychotic metabolic effects: A double blind controlled
clinical trial.
28. Tadmor H, Golani I, Doron R, Kremer I, Shamir A.
Prog
Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:322-331. ErbB signaling
antagonist ameliorates behavioral deficit induced by phencyclidine (PCP) in
mice, without affecting metabolic syndrome markers.
29. Vuk A, Baretic M, Osvatic MM, Filipcic I, Jovanovic N, Kuzman M. J Clin
Psychopharmacol. 2017 Oct;37(5):584-589. Treatment of Diabetic Ketoacidosis
Associated With Antipsychotic Medication: Literature Review.
30. Ronaldson K CNS Drugs. 2017 Sep;31(9):777-795. Cardiovascular Disease
in Clozapine-Treated Patients: Evidence, Mechanisms and Management.
31. Lord C, Wyler S, Wan R, Castorena C, Ahmed N, Mathew D, Lee S, Liu C,
Elmquist J. J Clin Invest. 2017 Sep 1;127(9):3402-3406. The atypical
antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.
32. Courty E, Gobalakichenane P, Garcia M, Muscat A, Kazakian C, Ledent T,
Moldes M, Blondeau B, Mitanchez D, Buyse M, Fève B. Diabetes Metab. 2018
Jun;44(3):281-291. Antenatal antipsychotic exposure induces multigenerational
and gender-specific programming of adiposity and glucose tolerance in adult
mouse offspring.
33. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M,
Stubbs B, Monaco F, Vieta E, Seeman M, Correll C, Carvalho A. Ther Clin Risk
Manag. 2017 Jun 29;13:757-777. Safety, tolerability, and risks associated with
first- and second-generation antipsychotics: a state-of-the-art clinical review.
34. Gu X, Chen R, Sun C, Zheng W, Yang X, Wang S, Ungvari G, Ng C,
Golenkov A, Lok G, Li L, Chow I, Wang F, Xiang Y. J Int Med Res. 2018
Jan;46(1):22-32. Effect of adjunctive ranitidine for antipsychotic-induced weight
gain: A systematic review of randomized placebo-controlled trials.
35. Pringsheim T, Kelly M, Urness D, Teehan M, Ismail Z, Gardner D. Can J
Psychiatry. 2017 Sep;62(9):673-683. Physical Health and Drug Safety in
Individuals with Schizophrenia.
36. Bilgiç S, Korkmaz D, Azirak S, Güvenç A, Kocaman N, Özer M. Oxid Med
Cell Longev. 2017;2017:8709521. Risperidone-Induced Renal Damage and
Metabolic Side Effects: The Protective Effect of Resveratrol.
37. Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane J.Int Clin
Psychopharmacol. 2017 Nov;32(6):319-328. Safety and tolerability of
cariprazine in patients with acute exacerbation of schizophrenia: a pooled
analysis of four phase II/III randomized, double-blind, placebo-controlled
studies.
38. Kanji S, Fonseka T, Marshe V, Sriretnakumar V, Hahn M, Müller D. Eur
Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):3-15. The microbiome-gut-
brain axis: implications for schizophrenia and antipsychotic induced weight gain.